Search
Erythromycin
go.drugbank.com/drugs/DB00199ApprovedInvestigationalVet approved[L5245,L7261] It is available for administration in various forms, including intravenous, topical, and eye drop preparations.[L5245] … It was originally discovered in 1952.[L5245] Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseSynonyms: 3''-O-demethylerythromycinCollagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigational[L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women. … [L14882] The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers.
Categories: Preparations for Treatment of Wounds and UlcersProducts: Iruxolum Mono SalbeErgocalciferol
go.drugbank.com/drugs/DB00153ApprovedInvestigationalNutraceuticalErgocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932. … These modifications reduce the affinity of ergocalciferol for the vitamin D binding protein resulting in faster clearance, limits its activation, and alters its catabolism.
Mixtures: TAMIPOOL FOR INJECTION, Vitalipid NProducts: VITAMINA D2 SALFBevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigationalfor intravitreal injection, which received European Commission and MHRA marketing authorization in 2024 and FDA approval on July 24, 2026 for the treatment of wet AMD. … [A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically
Categories: Experimental Unapproved Treatments for COVID-19Products: KRABEVA Bevacizumab (r-DNA Origin) Concentrate for Solution for Intravenous Infusion 25mg/mL, BEVAX 100MG/4 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability. … [A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.
Products: OPDIVO CONCENTRATE FOR SOLUTION FOR INFUSION 10 MG/ML, Opdivo 10mg/ml, Concentrate for solution for infusionGonadorelin
go.drugbank.com/drugs/DB00644ApprovedInvestigationalVet approvedGonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. … GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.
Mixtures: Relisorm 500 for Inj.-pws Liq-kit IV Sc, Relisorm 100 for Inj.-pws Liq-kit Sc IVCategories: Tests for Fertility DisturbancesDaunorubicin
go.drugbank.com/drugs/DB00694ApprovedInvestigationalA very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Categories: Topoisomerase II InhibitorsProducts: DAUNOCIN FOR INJ, DAUNOCIN FOR INJECTION 20 mg/vialPheniramine
go.drugbank.com/drugs/DB01620ApprovedPheniramine is a first-generation antihistamine in the alkylamine class, similar to [brompheniramine] and [chlorpheniramine]. … [A181628] It is used in some over-the-counter allergy as well as cold & flu products in combination with other drugs.
Mixtures: Rx Act Flu and Sore Throat, THERAFLU® N GRANULADO PARA SOLUCION ORALCategories: Antihistamines for Systemic Use, Antihistamines for Topical UseEnglish sole
go.drugbank.com/drugs/DB10904ApprovedEnglish sole allergenic extract is used in allergenic testing.
Categories: Non-Standardized Food Allergenic ExtractSynonyms: English soleRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalFDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].
Categories: Biologics for Rheumatoid Arthritis Treatment, CHOP-R chemotherapy regimenProducts: Mabthera Concentrate for Solution for Infusion 100mg/10ml, TRUXIMA® CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML